The role of Staphylococcus aureus in cystic fibrosis pathogenesis and clinico-microbiological interactions
- PMID: 38678689
- DOI: 10.1016/j.diagmicrobio.2024.116294
The role of Staphylococcus aureus in cystic fibrosis pathogenesis and clinico-microbiological interactions
Abstract
Cystic fibrosis (CF) is a progressive and inherited disease that affects approximately 70000 individuals all over the world annually. A mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene serves as its defining feature. Bacterial infections have a significant impact on the occurrence and development of CF. In this manuscript, we discuss the role and virulence factors of Staphylococcus aureus as an important human pathogen with the ability to induce respiratory tract infections. Recent studies have reported S. aureus as the first isolated bacteria in CF patients. Methicillin-resistant Staphylococcus aureus (MRSA) pathogens are approximately resistant to all β-lactams. CF patients are colonized by MRSA expressing various virulence factors including toxins, and Staphylococcal Cassette Chromosome mec (SCCmec) types, and have the potential for biofilm formation. Therefore, variations in clinical outcomes will be manifested. SCCmec type II has been reported in CF patients more than in other SCCmec types from different countries. The small-colony variants (SCVs) as specific morphologic subtypes of S. aureus with slow growth and unusual properties can also contribute to persistent and difficult-to-treat infections in CF patients. The pathophysiology of SCVs is complicated and not fully understood. Patients with cystic fibrosis should be aware of the intrinsic risk factors for complex S. aureus infections, including recurring infections, physiological issues, or coinfection with P. aeruginosa.
Keywords: Cystic fibrosis; Immunological interactions; Pathogenesis pathways; Staphylococcus aureus.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no conflict of interest.
Similar articles
-
Genotypic and Phenotypic Diversity of Staphylococcus aureus Isolates from Cystic Fibrosis Patient Lung Infections and Their Interactions with Pseudomonas aeruginosa.mBio. 2020 Jun 23;11(3):e00735-20. doi: 10.1128/mBio.00735-20. mBio. 2020. PMID: 32576671 Free PMC article.
-
Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis.Ann Am Thorac Soc. 2015 Jun;12(6):864-71. doi: 10.1513/AnnalsATS.201412-596OC. Ann Am Thorac Soc. 2015. PMID: 25745825 Free PMC article.
-
The Virulence Potential of Livestock-Associated Methicillin-Resistant Staphylococcus aureus Cultured from the Airways of Cystic Fibrosis Patients.Toxins (Basel). 2020 May 30;12(6):360. doi: 10.3390/toxins12060360. Toxins (Basel). 2020. PMID: 32486247 Free PMC article.
-
Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.Ann Am Thorac Soc. 2014 Sep;11(7):1120-9. doi: 10.1513/AnnalsATS.201402-050AS. Ann Am Thorac Soc. 2014. PMID: 25102221 Free PMC article. Review.
-
Pulmonary infections in patients with cystic fibrosis.Semin Respir Infect. 2002 Mar;17(1):47-56. doi: 10.1053/srin.2002.31690. Semin Respir Infect. 2002. PMID: 11891518 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical